Drug launches during COVID-19 was a significant topic during the Summit. A recent TGaS benchmarking survey showed that 89 percent of companies have had an impact to their pre-launch activities due to COVID-19, with almost half of these companies reporting high impact.
One white paper that was distributed to attendees at the Summit was entitled: Approaching Launch in the Age of COVID-19, The New Normal for Drug Launches: How to Shift and Stay Ahead of the Curve. The paper finds that there are four “must-have” needs to set the stage for a successful launch during the pandemic:
- Recognize and adopt a mindset of change
- Customer-driven flexibility
- Organizational flexibility: planning, communication and alignment
- Data-driven flexibility
“The show must go on,” said Curt Staab, SVP, TGaS Advisors, a division of Trinity. “Drugs will and must launch during this pandemic, but a shift in mindset is needed to ensure success. The needs we detail in this paper are not new, they have been taking root for many years, but COVID-19 is bringing them to the surface and accelerating the need for pharma teams to be flexible and agile.”
A copy of Approaching Launch in the Age of COVID-19, The New Normal for Drug Launches: How to Shift and Stay Ahead of the Curve can be acquired on TrinityLifeSciences.com.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
Media Contact
Richard Lorenzen
Fifth Avenue Brands
rlorenzen@fifthavenuebrands.com